Paroxysmal Hemicrania vs. SUNCT: Differentiating Rare Autonomic Cephalalgias

Within the spectrum of Trigeminal Autonomic Cephalalgias (TACs), differentiating between less common primary headache types - specifically Paroxysmal Hemicrania (PH) and Short-lasting Unilateral Neuralgiform Headache Attacks with Conjunctival Injection and Tearing (SUNCT) - is essential. While both share the core characteristics of unilateral trigeminal distribution pain and cranial autonomic features, their temporal patterns, trigger mechanisms, and pharmacological responses differ significantly.

Paroxysmal Hemicrania presents with pain characteristics similar to cluster headaches, typically described as throbbing, sharp, or boring in nature. Pain centers around the orbital and temporal regions. However, individual attacks are shorter in duration, typically lasting between 2 and 30 minutes. Attack frequency is noticeably higher than cluster headaches, ranging from 1 to 40 attacks per day, with most active periods exceeding 5 attacks per day more than half the time. The gender distribution shows an equal or slight female predominance (F:M ratio ranging from 1:1 to 2.7:1).

SUNCT (and its related variant, SUNA) represents the briefest and often most frequent TAC disorder. The pain is characteristically described as burning, stabbing, or sharp in the periorbital area. Key clinical differences between these two rare headache conditions include:

• Attack Duration: SUNCT attacks are ultra-brief, lasting anywhere from 1 to 600 seconds (5 to 240 seconds on average). Paroxysmal Hemicrania attacks last longer, spanning 2 to 30 minutes.

• Attack Frequency: SUNCT features extremely high daily attack rates, ranging from 1 to 200 episodes per day. Paroxysmal Hemicrania features 1 to 40 episodes daily.

• Prominent Features: SUNCT exhibits prominent conjunctival injection and lacrimation. Additionally, SUNCT attacks can be triggered by cutaneous stimuli (such as touching the face, chewing, or washing), a feature absent in cluster headache and paroxysmal hemicrania.

The most definitive diagnostic differentiator for Paroxysmal Hemicrania is its absolute, complete responsiveness to Indomethacin. A complete response to trial doses of indomethacin confirms the diagnosis of Paroxysmal Hemicrania, whereas indomethacin has no clinical effect on cluster headache or SUNCT.

Abortive therapies are ineffective for Paroxysmal Hemicrania due to its rapid resolution. Conversely, acute management of SUNCT often requires intravenous infusions of lidocaine. For long-term prophylaxis, Indomethacin remains the gold standard for Paroxysmal Hemicrania. SUNCT management relies on anticonvulsant prophylaxis, with Lamotrigine, Topiramate, and Gabapentin serving as primary options.